Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.
The increasing demand for molecular diagnostic of HBV (hepatitis B virus) and HCV (hepatitis C virus) infections is one of the primary drivers for the growth of this market. Molecular diagnosis simplifies sample preparation for high-volume testing and includes identification and profiling of causative agents of infection and the quantification of pathogens to monitor durability of therapy; thus, resulting in sales of around 60% of the overall molecular diagnosis market. Additionally, new companies are also focusing on the development of new products, which, in turn, is expected to change market dynamics for the diagnosis of HBV and HCV infections. For instance, Cepheid recently announced a quantitative test that offers on-demand molecular testing for confirmation of infection and monitoring of HCV and has obtained CE-IVD (in vitro diagnostics) status under the European Directive on in-vitro diagnostic medical devices, making it one of the leading platforms for molecular diagnosis.

Market Analysis and Insights: Global Hepatitis B and C Diagnostics Market
The global Hepatitis B and C Diagnostics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hepatitis B and C Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hepatitis B and C Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hepatitis B and C Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hepatitis B and C Diagnostics market.

Global Hepatitis B and C Diagnostics Scope and Market Size
Hepatitis B and C Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hepatitis B and C Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Hepatitis B
Hepatitis C

Segment by Application
Immunodiagnostics
Nucleic Acid Test (NAT)

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche Diagnostics
Abbott
Siemens
Qiagen
Abbott
bioMérieux
Cepheid
Chembio Diagnostics
DiaSorin
Enzo Life Sciences
Hologic
MedMira
OraSure Technologies
Quest Diagnostics
Quidel Corp
Randox Laboratories